May 7 |
4DMT to Participate in Upcoming Investor Conference
|
May 1 |
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
May 1 |
4DMT Announces Presentations at ARVO 2024 Annual Meeting
|
Apr 29 |
4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
|
Apr 18 |
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
|
Apr 15 |
4D Molecular Therapeutics new overweight at Barclays on genetic medicine platform
|
Apr 4 |
4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares
|
Mar 29 |
4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares
|
Mar 28 |
4D Molecular slips after regulatory update on lead asset
|
Mar 28 |
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
|